JP2025100670A5 - - Google Patents
Info
- Publication number
- JP2025100670A5 JP2025100670A5 JP2025064594A JP2025064594A JP2025100670A5 JP 2025100670 A5 JP2025100670 A5 JP 2025100670A5 JP 2025064594 A JP2025064594 A JP 2025064594A JP 2025064594 A JP2025064594 A JP 2025064594A JP 2025100670 A5 JP2025100670 A5 JP 2025100670A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- use according
- oncolytic virus
- immunomodulatory agent
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306470P | 2016-03-10 | 2016-03-10 | |
| US62/306,470 | 2016-03-10 | ||
| JP2018545432A JP7208492B2 (ja) | 2016-03-10 | 2017-03-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2021148497A JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023033622A Division JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025100670A JP2025100670A (ja) | 2025-07-03 |
| JP2025100670A5 true JP2025100670A5 (cg-RX-API-DMAC7.html) | 2025-11-11 |
Family
ID=59789875
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545432A Active JP7208492B2 (ja) | 2016-03-10 | 2017-03-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2021148497A Active JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A Pending JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2025064594A Pending JP2025100670A (ja) | 2016-03-10 | 2025-04-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545432A Active JP7208492B2 (ja) | 2016-03-10 | 2017-03-09 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2021148497A Active JP7455399B2 (ja) | 2016-03-10 | 2021-09-13 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
| JP2023033622A Pending JP2023060184A (ja) | 2016-03-10 | 2023-03-06 | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11497781B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3426271B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7208492B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108778301A (cg-RX-API-DMAC7.html) |
| ES (1) | ES3041500T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3426271T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017156349A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| WO2016177682A1 (en) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー, インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| WO2017096201A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| WO2018170133A1 (en) * | 2017-03-15 | 2018-09-20 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
| EP3610026B1 (en) | 2017-04-14 | 2025-05-14 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| MX2019012741A (es) | 2017-04-28 | 2020-01-21 | Merck Sharp & Dohme | Biomarcadores para agentes terapeuticos contra el cancer. |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| MX2020000993A (es) | 2017-07-26 | 2020-07-22 | Oncorus Inc | Vectores virales oncolíticos y usos de estos. |
| KR20200078483A (ko) * | 2017-10-27 | 2020-07-01 | 머크 샤프 앤드 돔 코포레이션 | 간암 치료를 위한 조성물 및 방법 |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| JP7550449B2 (ja) * | 2018-04-02 | 2024-09-13 | デューク ユニバーシティ | ネオアジュバントがん治療 |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| TWI787500B (zh) * | 2018-04-23 | 2022-12-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN110819657B (zh) * | 2018-08-10 | 2021-11-19 | 睿丰康生物医药科技(浙江)有限公司 | 一种减毒棒状病毒的制备方法及应用 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| TWI690597B (zh) * | 2018-11-14 | 2020-04-11 | 國立中央大學 | 泌尿上皮癌的檢測套組及檢測方法 |
| TW202600150A (zh) * | 2019-01-25 | 2026-01-01 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| CA3152796A1 (en) * | 2019-08-27 | 2021-03-04 | Turnstone Biologics Corp. | Methods for inducing an immune response against neoantigens |
| JP2023501539A (ja) | 2019-11-12 | 2023-01-18 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用 |
| KR20230012484A (ko) * | 2020-05-20 | 2023-01-26 | 바이로큐어 주식회사 | 암 예방 또는 치료용 약학적 조성물 |
| JP2023539454A (ja) | 2020-08-12 | 2023-09-14 | アクティム・セラピューティクス・インコーポレイテッド | 免疫刺激細菌ベースのワクチン、治療薬およびrnaデリバリープラットフォーム |
| WO2022040365A1 (en) * | 2020-08-18 | 2022-02-24 | Curators Of The University Of Missouri | Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| CN114681612B (zh) * | 2020-12-30 | 2024-10-25 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物及其制备方法和应用 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| WO2023141229A2 (en) * | 2022-01-19 | 2023-07-27 | Istari Oncology, Inc. | Oncolytic virus regimens for the treatment of cancer |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024054293A1 (en) * | 2022-09-08 | 2024-03-14 | Research Institute At Nationwide Children's Hospital | Oncolytic virus combination to maximize oncolytic activity |
| WO2024054989A1 (en) * | 2022-09-08 | 2024-03-14 | Seneca Therapeutics, Inc. | Cancer therapies with oncolytic virus and an immune checkpoint inhibitor |
| AU2023367780A1 (en) | 2022-10-25 | 2025-03-27 | Barinthus Biotherapeutics North America, Inc. | Self-assembling nanoparticles |
| JP2025541309A (ja) * | 2022-12-15 | 2025-12-18 | カリヴィル イムノセラピューティクス, インコーポレイテッド | Cd47/sirp-アルファ免疫チェックポイント阻害剤の組成物およびその使用 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
| WO2025251009A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent |
| WO2025251003A1 (en) * | 2024-05-31 | 2025-12-04 | Cg Oncology, Inc. | Methods of treating bladder cancer using an oncolytic virus |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US297A (en) | 1837-07-29 | Improvement in fire-arms | ||
| US7250A (en) | 1850-04-02 | Improved surface-condenser for steam-engines | ||
| US4590071A (en) | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| SE8701004D0 (sv) | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| WO1994004570A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| FI961285L (fi) | 1993-10-01 | 1996-03-20 | Immunex Corp | CD40:n vasta-aineita |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| US7001764B2 (en) | 1995-06-27 | 2006-02-21 | Cell Genesys, Inc. | Compositions comprising tissue specific adenoviral vectors |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6432700B1 (en) | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| WO1998039464A2 (en) | 1997-03-03 | 1998-09-11 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| AU2003252891B2 (en) | 1998-09-10 | 2006-06-01 | Cold Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US20080213778A1 (en) | 1998-12-30 | 2008-09-04 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
| US7041474B2 (en) | 1998-12-30 | 2006-05-09 | Millennium Pharmaceuticals, Inc. | Nucleic acid encoding human tango 509 |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6687360B2 (en) | 1999-12-30 | 2004-02-03 | At&T Corp. | Personal IP follow-me service |
| MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
| JP2004511203A (ja) | 2000-03-24 | 2004-04-15 | セル ジェネシス インコーポレーティッド | 内部リボソーム接近部位を含む細胞特異的なアデノウイルスベクター |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| US7048920B2 (en) | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| WO2002000692A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7459154B2 (en) | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| WO2005030261A1 (en) * | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| US20050282280A1 (en) | 2003-08-28 | 2005-12-22 | Ennist David L | Oncolytic adenoviral vectors encoding GM-CSF |
| US20050186178A1 (en) | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
| TW200607859A (en) | 2004-08-23 | 2006-03-01 | Cell Genesys Inc | Oncolytic adenoviral vectors encoding GM-CSF |
| US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
| PL1810026T3 (pl) | 2004-10-06 | 2018-08-31 | Mayo Foundation For Medical Education And Research | B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego |
| EP1877090B1 (en) | 2005-05-06 | 2014-01-15 | Providence Health System | Trimeric ox40-immunoglobulin fusion protein and methods of use |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| US8557257B2 (en) | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| WO2007123737A2 (en) | 2006-03-30 | 2007-11-01 | University Of California | Methods and compositions for localized secretion of anti-ctla-4 antibodies |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US9345787B2 (en) | 2008-12-22 | 2016-05-24 | Targovax Oy | Adenoviral vectors and methods and uses related thereto |
| BRPI0924123B8 (pt) | 2008-12-22 | 2021-05-25 | Oncos Therapeutics Oy | vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| RU2013118723A (ru) * | 2010-09-24 | 2014-10-27 | Онкос Терапьютикс Ой | Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4 |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| US9056133B2 (en) | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US10238698B2 (en) * | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AU2013296919A1 (en) * | 2012-07-30 | 2015-01-22 | Alex Wah Hin Yeung | Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator |
| EP3461491B1 (en) | 2013-04-18 | 2024-11-13 | TILT Biotherapeutics Oy | Enhanced adoptive cell therapy |
| CN114317461A (zh) | 2013-11-22 | 2022-04-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| JP6954648B2 (ja) * | 2015-10-19 | 2021-10-27 | シージー オンコロジー, インコーポレイテッド | 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法 |
| US11497781B2 (en) | 2016-03-10 | 2022-11-15 | Cg Oncology, Inc. | Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor |
| EP3610026B1 (en) | 2017-04-14 | 2025-05-14 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
-
2017
- 2017-03-09 US US16/083,709 patent/US11497781B2/en active Active
- 2017-03-09 EP EP17764159.4A patent/EP3426271B1/en active Active
- 2017-03-09 JP JP2018545432A patent/JP7208492B2/ja active Active
- 2017-03-09 ES ES17764159T patent/ES3041500T3/es active Active
- 2017-03-09 CN CN201780015149.9A patent/CN108778301A/zh active Pending
- 2017-03-09 WO PCT/US2017/021694 patent/WO2017156349A1/en not_active Ceased
- 2017-03-09 PL PL17764159.4T patent/PL3426271T3/pl unknown
-
2021
- 2021-09-13 JP JP2021148497A patent/JP7455399B2/ja active Active
-
2022
- 2022-08-26 US US17/822,677 patent/US12090183B2/en active Active
-
2023
- 2023-03-06 JP JP2023033622A patent/JP2023060184A/ja active Pending
-
2025
- 2025-02-12 US US19/051,663 patent/US20250302897A1/en active Pending
- 2025-04-09 JP JP2025064594A patent/JP2025100670A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114532B2 (ja) | 増強された養子細胞療法 | |
| US20250171745A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Msaouel et al. | Clinical trials with oncolytic measles virus: current status and future prospects | |
| Chiu et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors | |
| Haas et al. | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies | |
| CN100387710C (zh) | 原发性癌和转移性癌相关的核酸 | |
| JP2021500932A5 (cg-RX-API-DMAC7.html) | ||
| Jebar et al. | Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma | |
| JP2021533789A5 (cg-RX-API-DMAC7.html) | ||
| Zolaly et al. | The clinical advances of oncolytic viruses in cancer immunotherapy | |
| JP2007511507A (ja) | 癌を処置するための治療レジメン | |
| CN111363726A (zh) | 表达干扰素的溶瘤病毒及其应用 | |
| JP2020504767A (ja) | 武装した複製可能な腫瘍溶解性アデノウイルス | |
| JP2024045278A (ja) | グループbアデノウイルス含有製剤 | |
| JP2022536929A5 (cg-RX-API-DMAC7.html) | ||
| CN110573624A (zh) | 治疗膀胱癌的方法 | |
| JP2012516682A (ja) | 非Ad5アデノウイルスベクター並びに前記に関連する方法および使用 | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Cao et al. | Transarterial viroembolization improves the therapeutic efficacy of immune-excluded liver cancer: Three birds with one stone | |
| Wang et al. | Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors | |
| AU3570299A (en) | Adenovirus-chemotherapeutic combination for treating cancer | |
| Essand et al. | Oncolytic viruses for the treatment of neuroendocrine tumors | |
| Sharma et al. | Conditional replication of oncolytic virus based on detection of oncogenic mRNA | |
| WO2025119151A1 (zh) | Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用 | |
| Arguello | Development of adenoviral vectors armed with TNF-related therapeutic proteins for gene therapy |